Theory vs. Conclusion: An Ongoing Issue In Scientific Discussions

According to the CDC, "We are still learning about how the virus spreads and the severity of illness it causes," yet so much information about COVID-19 that we hear in the mainstream media (MSM) and from our Governor, members of the Federal COVID-19 Task Force and popular TV Doctors is presented purely as "fact." Any alternative viewpoints are often dismissed, quieted or suppressed. 

Did you know?

“Coronaviruses have the largest RNA genome of any of the animal viruses [and have a lot of secrets].” - Dr. McIntosh

 

Read more on Forbes.com

 

Mass Vaccinations During a Pandemic

Geerrt Vanden Bossche, Phd, DVM is an Independent Researcher who previously served as the Head of Vaccine Development for the German Centre for Infection Research, and the Program Manager for the Global Alliance for Vaccines and Immunisation (GAVI) — a collaboration between the World Health Organization, Bill & Melinda Gates Foundation, CDC, and UNICEF. Dr. Bossche also served as the Senior Program Officer of Global Health and Vaccine Discovery for the Bill & Melinda Gates Foundation.

 

Available COVID-19 Vaccines

According to an article on icandecide.org: Many Americans have been led to believe that a COVID-19 vaccine will prevent individuals from having a serious case of COVID-19 and will stop people from spreading it to others. However, the clinical trials for Pfizer, Moderna, AstraZeneca, and Johnson & Johnson’s products are not designed to determine either of these. 

 

Both Pfizer and Moderna published data suggesting that COVID-19 vaccines might reduce the spread of virus, but the data requires closer scrutiny according to many mainstream media outlets, including Time Magazine.

Time Magazine reports of COVID-19 design of vaccines

The FDA initially only provided Emergency Use Authorization (EUA) of three separate COVID-19 vaccines in 2020, and then later gave approval to Pfizer’s COVID-19 vaccine Monday, August 23, 2021 under the title "COMIRNATY." Since the announcement, some health freedom advocates suggest that rebranding the Pfizer-BioNTech vaccine allows Moderna and Janssen—as well as the originally branded Pfizer COVID-19 vaccine—to remain under EUA and distribution since COMIRNATY is not readily available as of yet.* 

 

You can find the latest information about authorization vs. approval at the following FDA web address: FDA.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines

Regarding Pfizer's COMIRNATY COVID-19 Vaccine

“... it’s concerning that full approval is based on only six months’ worth of data — despite clinical trials designed for two years — and there’s no control group after Pfizer offered the product to placebo participants before the trials were completed.” - Kim Witczak, a drug safety advocate who serves as a consumer representative on the FDA’s Psychopharmacologic Drugs Advisory Committee

Read more on ChildrensHealthDefense.org

Pfizer-BioNTech

On December 11, 2020, the FDA issued the first emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine to be distributed in the U.S. for use in individuals 16 years and older.

View the Fact Sheets on FDA.gov

View the BLA approval on FDA.gov

Paper Abstract

Moderna**

On December 18, 2020, the FDA issued the second emergency use authorization (EUA) for the Moderna COVID-19 Vaccine to be distributed in the U.S for use in individuals 18 years and older.

View the Fact Sheets on FDA.gov

Janssen

On February 27, 2021, the FDA issued the third emergency use authorization (EUA) for the Janssen COVID-19 Vaccine to be distributed in the U.S. for use in individuals 18 years and older.

View the Fact Sheets on FDA.gov

*This information may be updated since publishing.

 

**Citing insufficient data, the World Health Organization’s latest guidance on Moderna’s COVID vaccine recommends most pregnant women, and anyone under age 18, not get the vaccine. Read more at Pregnant or Under 18? Don’t Get Moderna’s COVID Vaccine, WHO Says • Children's Health Defense

 

COVID-19 Vaccine Studies

Incomplete Pfizer-BioNTech studies and their completion dates

 

Reference: 
BLA approval letter (FDA.gov)

Deferred pediatric Study to evaluate the safety and effectiveness of COMIRNATY in children 12 years through 15 years of age.

Study Completion: May 31, 2023

Deferred pediatric Study to evaluate the safety and effectiveness of COMIRNATY in infants and children 6 months to <12 years of age.

Study Completion: November 30, 2023

Deferred pediatric Study to evaluate the safety and effectiveness of COMIRNATY in infants <6 months of age.

Study Completion: July 31, 2024 

Study to describe the natural history of myocarditis and pericarditis following administration of COMIRNATY.

Study Completion: March 31, 2024

Study: Vaccinated carry 251 times the load of COVID-19 viruses in their nostrils compared to unvaccinated

Oxford University Clinical Research Group

The Lancet  August 10, 2021

Study: Vaccinated may play a key role in helping SARS-CoV-2 variants

Scientific Reports  July 30, 2021

More coming to this section soon.

 

Vaccine Reactions

Yale researchers identified several specific sex-linked immune system differences that can impact on male susceptibility to severe COVID-19, as well as to female heightened reactivity to COVID-19 vaccination. It appeared that women tended to mount a stronger T-cell response to infection in general. In contrast, men in the early stages of COVID-19 infection showed higher levels of cytokines, inflammatory proteins involved in the “first response” to invading pathogens.

Read the full article at the vaccinereaction.org

News from Around the Web

More coming to this section soon.